Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

Robert John Motzer, Camillo Porta, Nicholas J. Vogelzang et al. · The Lancet Oncology · 2014

Cited by 262 works. doi:10.1016/s1470-2045(14)70030-0

Authors

References